{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T02:18:17Z","timestamp":1649038697721},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.lpm.2009.02.005","type":"journal-article","created":{"date-parts":[[2009,3,18]],"date-time":"2009-03-18T10:13:19Z","timestamp":1237371199000},"page":"788-798","source":"Crossref","is-referenced-by-count":2,"title":["Anti-CD20 en oncoh\u00e9matologie"],"prefix":"10.1016","volume":"38","author":[{"given":"No\u00ebl","family":"Milpied","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2009.02.005_bib1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib2","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1200\/JCO.2004.06.003","article-title":"Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype","volume":"22","author":"Weng","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib3","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3324\/haematol.11288","article-title":"Fc{gamma}RIIIA and Fc{gamma}RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab","volume":"92","author":"Carlotti","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.lpm.2009.02.005_bib4","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood.V108.11.486.486","article-title":"Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): Survival analysis with extended follow-up (F\/up) of 7 years","volume":"108","author":"Colombat","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib7","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib9","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib10","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib11","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib12","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib13","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.lpm.2009.02.005_bib14","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib15","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib16","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by the GOELAMS. Final results with a median follow-up of nine years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib17","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib18","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose, therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib19","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: A GELA Study","volume":"26","author":"Sebban","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib20","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","article-title":"Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients","volume":"99","author":"Timmerman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib21","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1200\/JCO.2007.13.7729","article-title":"Granulocyte-macrophage colony stimulating factor potentiates rituximab therapy in patients with relapsed follicular lymphoma: Results of a phase II study","volume":"26","author":"Cartron","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib22","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib23","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib24","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib25","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"Van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib26","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood.V112.11.836.836","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: Long term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"112","author":"Van Oers","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2008.261","volume":"23","author":"Buske","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.lpm.2009.02.005_bib28","doi-asserted-by":"crossref","unstructured":"Treon SP, Gertz MA, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan AR et al. Update on treatment recommendations from the Third international workshop on Waldenstrom's macroglobulinemia. Blood 2006; 107:3442\u20136.","DOI":"10.1182\/blood-2005-02-0833"},{"key":"10.1016\/j.lpm.2009.02.005_bib29","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-Cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2141.2003.04586.x","article-title":"Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma","volume":"123","author":"Martinelli","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.lpm.2009.02.005_bib31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000074641","article-title":"Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma","volume":"65","author":"Raderer","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.lpm.2009.02.005_bib32","first-page":"1046","article-title":"Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukaemia","volume":"86","author":"Lauria","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.lpm.2009.02.005_bib33","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1182\/blood-2003-02-0630","article-title":"Rituximab in relapsed or refractory hairy cell leukaemia","volume":"102","author":"Thomas","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib34","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib35","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib36","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2002-03-0972","article-title":"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia","volume":"100","author":"Schulz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib37","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib38","doi-asserted-by":"crossref","unstructured":"Robak T, Moiseev SI, Dmoszynska A, Solal-C\u00e9ligny P, Warzocha K, Loscertales J et al. Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial. ASH 2008. http:\/\/ash.confex.com\/ash\/2008\/webprogram\/Paper15742.html.","DOI":"10.1182\/blood.V112.11.lba-1.lba-1"},{"key":"10.1016\/j.lpm.2009.02.005_bib39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib40","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib41","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukaemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.V112.11.325.325","volume":"112","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib43","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib44","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2009.02.005_bib46","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1182\/blood-2002-11-3442","article-title":"Rituximab plus CHOP (R-CHOP) overcomes bcl-2\u2013associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)","volume":"101","author":"Mounier","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib47","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019etude des lymphomes de l\u2019adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet oncology"},{"key":"10.1016\/j.lpm.2009.02.005_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib50","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11060-006-9217-y","article-title":"Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma","volume":"81","author":"Antonini","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib52","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin's lymphoma: AIDS-malignancies consortium trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib53","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","article-title":"Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma","volume":"24","author":"Boue","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib54","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/CCO.0b013e3283094ec7","article-title":"Management of AIDS-related lymphoma","volume":"20","author":"Levine","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib55","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP vs CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib56","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma andmall B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib57","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib58","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib59","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo\u2013purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib60","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1182\/blood.V92.9.3137","article-title":"Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome","volume":"92","author":"Benkerrou","year":"1998","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2009.02.005_bib61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1008372814223","article-title":"Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients","volume":"11","author":"Milpied","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lpm.2009.02.005_bib62","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2005-01-0377","article-title":"Efficacy and safety of rituximab in B-Cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study","volume":"107","author":"Choquet","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib63","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V101.2.420","article-title":"Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin lymphoma study group","volume":"101","author":"Rehwald","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2009.02.005_bib64","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498209000979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498209000979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T22:11:06Z","timestamp":1589667066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498209000979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0755498209000979"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2009.02.005","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}